Living a Full Life after Inflammatory Breast Cancer

0

When Trish Vickery learned in 2013 that she had inflammatory breast cancer, she knew all too well the gravity of her diagnosis. Her mother had died from the disease.

Yet Vickery is living a full and energetic life — working, traveling, exercising, rowing on the Charles River in Boston, and spending time with her husband and young adult daughter and son.

“Today, doing well with this cancer is a reality,” says Vickery’s doctor Beth Overmoyer, MD, who directs the Inflammatory Breast Cancer Program at Dana-Farber’s Susan F. Smith Center for Women’s Cancers.

Overmoyer emphasizes that she and her colleagues at Dana-Farber understand the biology of the disease and can apply their knowledge and experience, offering state-of-the-art therapies.

Inflammatory breast cancer comes on very suddenly and is more aggressive than other types of breast cancer,” she says. “It is very important to seek care, right away, from a cancer center that specializes in inflammatory breast cancer and understands the latest research and treatment.”

Vickery, 58, says that one of the luckiest days of her life was the day she walked into Dana-Farber.

“Dr. Overmoyer explained each step and cared about me as a person,” she recalls.

Because her cancer was HER2 positive, Vickery underwent chemotherapy, a mastectomy, radiation, and treatment with Herceptin.

Vickery offers the following advice for anyone diagnosed with inflammatory breast cancer:

  • Seek care from a team that specializes in this type of cancer and is up on the latest research.
  • Don’t Google it. The statistics are outdated and can be scary. Focus on you.
  • This will be a tough regimen. Take it one day at a time.
  • You can survive this.

 

Beth Overmoyer, breast cancer, inflammatory

Beth Overmoyer confers with colleague Lynn Colicchio.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber clinicians have been involved in the development of several new agents approved recently for B-cell acu… https://t.co/Oo3SiY79EN
Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.